🔬 Now at Pharmidex: The 8HUM Model
July 21, 2025
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs.
✅ Human-relevant metabolism data
✅ Supports IND-enabling & regulatory studies
✅ Ideal for metabolite profiling, DDI risk & toxicity assessment
By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development.
📩 Contact us to see how 8HUM can support your project.
#Pharmidex #8HUM #DrugMetabolism #DMPK #PreclinicalResearch #InVivoPharmacology #DrugDevelopment
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
